Principal Financial Group
PCVX icon

Principal Financial Group’s Vaxcyte PCVX Stock Holding History

Principal Financial Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.8M Buy
329,975
+322,264
+4,179% +$18.8M 0.01% 1012
2026
Q2 		$448K Buy
7,711
+2,436
+46% +$132K ﹤0.01% 2016
2026
Q1 		$307K Buy
5,275
+343
+7% +$18.6K ﹤0.01% 2069
2025
Q4 		$228K Sell
4,932
-3,062
-38% -$137K ﹤0.01% 2115
2025
Q3 		$288K Sell
7,994
-618
-7% -$20.5K ﹤0.01% 2125
2025
Q2 		$280K Sell
8,612
-460,949
-98% -$15.1M ﹤0.01% 2083
2025
Q1 		$17.7M Buy
469,561
+160,622
+52% +$12.8M 0.01% 907
2024
Q4 		$25.3M Buy
308,939
+256,237
+486% +$25.4M 0.01% 723
2024
Q3 		$6.02M Buy
52,702
+34,287
+186% +$3.09M ﹤0.01% 1499
2024
Q2 		$1.39M Sell
18,415
-6,182
-25% -$421K ﹤0.01% 1818
2024
Q1 		$1.68M Buy
24,597
+2,589
+12% +$179K ﹤0.01% 1800
2023
Q4 		$1.38M Buy
22,008
+376
+2% +$19.5K ﹤0.01% 1802
2023
Q3 		$1.1M Sell
21,632
-524
-2% -$25.9K ﹤0.01% 1828
2023
Q2 		$1.11M Buy
22,156
+4,848
+28% +$230K ﹤0.01% 1831
2023
Q1 		$649K Sell
17,308
-1,154
-6% -$49K ﹤0.01% 1917
2022
Q4 		$885K Buy
18,462
+4,190
+29% +$164K ﹤0.01% 1875
2022
Q3 		$342K Sell
14,272
-225
-2% -$5.7K ﹤0.01% 2046
2022
Q2 		$315K Buy
+14,497
New +$335K ﹤0.01% 2163
2021
Q4 		– Sell
-10,121
Closed -$257K – 2600
2021
Q3 		$257K Sell
10,121
-1,641
-14% -$39.8K ﹤0.01% 2349
2021
Q2 		$265K Buy
11,762
+448
+4% +$9.17K ﹤0.01% 2400
2021
Q1 		$223K Buy
11,314
+797
+8% +$20.1K ﹤0.01% 2354
2020
Q4 		$279K Buy
+10,517
New +$391K ﹤0.01% 2252

Other funds holding PCVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Principal Financial Group's PCVX Position: Q3 2026 in Review

Principal Financial Group increased its Vaxcyte (PCVX) stake by 4,179% in Q3 2026, buying an estimated $18.8M and bringing the position to 329,975 shares worth $18.8M. The position accounts for 0.01% of the portfolio, ranked #1012.

Principal Financial Group first reported a position in PCVX in Q4 2020 and has held it in 22 quarters since. The position peaked at $25.3M in Q4 2024. 127 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Principal Financial Group held 329,975 shares of Vaxcyte worth $18.8M as of Q3 2026.
  • Principal Financial Group bought 322,264 Vaxcyte shares in Q3 2026, an estimated $18.8M.
  • Vaxcyte made up 0.01% of Principal Financial Group's portfolio in Q3 2026, its #1012 holding.
  • Principal Financial Group first reported a position in Vaxcyte in Q4 2020 and has held it in 22 quarters since.
  • Principal Financial Group's Vaxcyte position peaked at $25.3M in Q4 2024.
  • 127 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Principal Financial Group's 13F filing for Q3 2026, filed 2 Nov 2026.